T. Moriwaki

发表

Predictive Factors of Lymph Node Metastasis in Patients With Undifferentiated Early Gastric Cancers

Tomohiro Nishina, Rieko Nishimura, I. Hyodo, 2006, Journal of clinical gastroenterology.

Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181

R. Ishihara, K. Muro, T. Satoh, 2021, Esophagus.

Ovarian metastases from ileum cancer in a patient with germline EPCAM gene deletion successfully treated with surgical resection and CAPOX chemotherapy: a case report

E. Noguchi, T. Moriwaki, T. Satoh, 2020, BMC Medical Genetics.

Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study

I. Hyodo, M. Mizuta, Yuji Watanabe, 2015, International Journal of Clinical Oncology.

Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma

T. Oda, H. Ishikawa, H. Sakurai, 2021, International Journal of Clinical Oncology.

A case of advanced gastric cancer showing HER2 positivity after chemotherapy

I. Hyodo, Yoshiyuki Yamamoto, T. Moriwaki, 2020, International Cancer Conference Journal.

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

N. Sugimoto, I. Hyodo, H. Shimodaira, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment

K. Yamashita, N. Sugimoto, K. Ando, 2021, Frontiers in Oncology.

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).

M. Ando, E. Baba, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)

E. Baba, I. Hyodo, K. Yamashita, 2012, Medical Oncology.

Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment

N. Sugimoto, Y. Shimada, A. Takashima, 2021, AntiCancer Research.

Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)

K. Yamashita, N. Sugimoto, K. Ando, 2021, Frontiers in Oncology.

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

Y. Shimada, E. Van Cutsem, N. Sugimoto, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study

H. Ueno, E. Oki, K. Yamashita, 2019, International Journal of Clinical Oncology.

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

K. Yamashita, E. Baba, N. Sugimoto, 2017, The oncologist.

Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.

I. Hyodo, Yoshiyuki Yamamoto, H. Kondo, 2019, European journal of cancer.

Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer

K. Mori, T. Moriwaki, T. Denda, 2020, Cancer Chemotherapy and Pharmacology.

Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)

T. Yamanaka, Masato Nakamura, I. Hyodo, 2020, Targeted Oncology.

Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).

I. Hyodo, M. Shimada, M. Mizuta, 2016, Clinical colorectal cancer.

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

N. Sugimoto, K. Muro, A. Ohtsu, 2012, The Lancet. Oncology.

Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis

I. Hyodo, Yoshiyuki Yamamoto, M. Gosho, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer

I. Hyodo, T. Yoshino, N. Boku, 2015, Cancer Chemotherapy and Pharmacology.

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Yoshiyuki Yamamoto, K. Nagashima, T. Nakajima, 2021, BMC Cancer.

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

T. Yamanaka, I. Hyodo, K. Nishio, 2016, Cancer science.

S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.

N. Sugimoto, I. Hyodo, M. Takeuchi, 2016, The Lancet Oncology.

Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis.

I. Hyodo, T. Moriwaki, A. Sugaya, 2016, Internal medicine.

Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status

I. Hyodo, Yoshiyuki Yamamoto, M. Nishi, 2014, Medical Oncology.

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

N. Sugimoto, I. Hyodo, H. Shinozaki, 2017, Gastric Cancer.

Risk factors for submucosal and lymphovascular invasion in gastric cancer looking indicative for endoscopic submucosal dissection

I. Hyodo, Hideo Suzuki, T. Narasaka, 2014, Gastric Cancer.

Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy

I. Hyodo, Yoshiyuki Yamamoto, M. Gosho, 2016, British Journal of Cancer.

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy

J. Furuse, M. Ikeda, D. Sakai, 2021, Cancer medicine.

Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden

I. Hyodo, Yoshiyuki Yamamoto, T. Moriwaki, 2020, International Journal of Clinical Oncology.

REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.

T. Yamanaka, K. Muro, T. Nishina, 2020, Future oncology.

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).

M. Takeuchi, M. Azuma, S. Tanabe, 2014, European journal of cancer.

A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer

I. Hyodo, Taketo Yamaguchi, K. Amagai, 2014, Gastric Cancer.

A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression

I. Hyodo, S. Sakashita, T. Moriwaki, 2018, Internal medicine.

Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

E. Baba, M. Saruta, N. Sugimoto, 2022, International Journal of Clinical Oncology.

Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol

K. Ariyoshi, T. Morita, Yoshiyuki Yamamoto, 2022, Contemporary clinical trials communications.

Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer

I. Hyodo, Takanobu Yamada, Ken Kato, 2022, JCO precision oncology.

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).

T. Yamanaka, I. Hyodo, K. Muro, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)

R. Yamashita, I. Hyodo, K. Ando, 2022, Journal of Cancer Research and Clinical Oncology.

Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

E. Baba, M. Saruta, N. Sugimoto, 2022, International Journal of Clinical Oncology.

A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).

M. Ando, E. Baba, I. Hyodo, 2014 .

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).

N. Sugimoto, K. Muro, A. Ohtsu, 2016 .

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient

Yoshiyuki Yamamoto, T. Moriwaki, T. Ikeda, 2020, Internal medicine.

PD-014Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030)

N. Sugimoto, K. Muro, A. Ohtsu, 2016 .

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer

E. Oki, N. Sugimoto, M. Chiron, 2019, Cancer science.

Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling

I. Hyodo, K. Yamato, Yoshiyuki Yamamoto, 2021, Oncology letters.

A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer

I. Hyodo, S. Hirasaki, J. Nasu, 2005, Cancer Chemotherapy and Pharmacology.

Phase I study of gemcitabine, cisplatin, and S‐1 combination therapy for patients with untreated advanced biliary tract cancer

I. Hyodo, T. Moriwaki, N. Hasegawa, 2015, Journal of hepato-biliary-pancreatic sciences.

Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review

Yoshiyuki Yamamoto, Keiichi Yamada, T. Narasaka, 2022, Internal medicine.

Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.

N. Sugimoto, I. Hyodo, H. Shimodaira, 2012 .

Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review

Yoshiyuki Yamamoto, K. Doki, T. Moriwaki, 2022, Cancer Chemotherapy and Pharmacology.

A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting.

H. Tajiri, I. Hyodo, J. Nasu, 2003, European journal of cancer.

Proton beam therapy combined with concurrent chemotherapy for esophageal cancer.

N. Ohkohchi, T. Hashimoto, I. Hyodo, 2014, Anticancer research.

Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR.

I. Hyodo, K. Yamato, Hideo Suzuki, 2013, Anticancer research.

Granular cell tumor occurring in the sigmoid colon treated by endoscopic mucosal resection using a transparent cap (EMR-C)

I. Hyodo, S. Hirasaki, T. Doi, 2003, Journal of Gastroenterology.

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer

E. Oki, Ken Kato, M. Shiozawa, 2020, Cancer science.

Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report

I. Hyodo, Yoshiyuki Yamamoto, T. Moriwaki, 2018, BMC Cancer.

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

T. Yamanaka, E. Baba, N. Sugimoto, 2018, The oncologist.

Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).

E. Baba, N. Sugimoto, I. Hyodo, 2020, European journal of cancer.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later‐line Chemotherapy in Patients With Metastatic Colorectal Cancer

H. Ueno, E. Oki, K. Yamashita, 2018, Clinical colorectal cancer.

Efficacy of clinical pathway for the management of mucosal gastric carcinoma treated with endoscopic submucosal dissection using an insulated-tip diathermic knife.

Y. Shiratori, I. Hyodo, S. Hirasaki, 2004, Internal medicine.

Acute pancreatitis occurring in gastric aberrant pancreas treated with surgery and proved by histological examination.

S. Hirasaki, J. Nasu, T. Moriwaki, 2005, Internal medicine.

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

I. Hyodo, Yoshiyuki Yamamoto, T. Nishina, 2022, International Journal of Clinical Oncology.

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells

I. Hyodo, K. Yamato, Hideo Suzuki, 2011, Cancer science.

MDM4 as a Prognostic Factor for Patients With Gastric Cancer With Low Expression of p53

I. Hyodo, K. Yamato, Yoshiyuki Yamamoto, 2021, AntiCancer Research.

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

E. Baba, H. Kitamura, I. Moriyama, 2017, International Journal of Clinical Oncology.

[A case of Cronkhite-Canada syndrome associated with cholangiocellular carcinoma].

I. Hyodo, S. Hirasaki, T. Nishina, 2005, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

UPPER GASTROINTESTINAL LESIONS IN PATIENTS WITH PANCREATIC CANCER

I. Hyodo, S. Hirasaki, J. Nasu, 2005 .

Multiple synchronous early gastric carcinoma with seven lesions

I. Hyodo, S. Hirasaki, T. Moriwaki, 2003, Journal of Gastroenterology.

Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Y. Kodera, Masato Nakamura, H. Ohdan, 2020, Gastric Cancer.

Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Y. Kodera, Masato Nakamura, H. Ohdan, 2020, Gastric Cancer.

Effectiveness of an endoscopic biopsy procedure using EUS-FNA and EMR-C for diagnosing adenocarcinoma arising from ectopic pancreas: two case reports and a literature review.

I. Hyodo, Yoshiyuki Yamamoto, Hideo Suzuki, 2014, Internal medicine.

Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report

I. Hyodo, Yoshiyuki Yamamoto, T. Moriwaki, 2018, BMC Cancer.

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

E. Oki, N. Sugimoto, D. Sakai, 2019, Cancer science.

Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment

Yoshiyuki Yamamoto, T. Moriwaki, Takeshi Yamada, 2023, AntiCancer Research.

Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program

R. Yamashita, E. Oki, K. Tsuchihara, 2023, JCO precision oncology.

Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

M. Ikeda, J. Odegaard, S. Itoh, 2023, British Journal of Cancer.

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

I. Hyodo, M. Shimada, Kazuma Kobayashi, 2019, International Journal of Clinical Oncology.

Biomarker Analysis in A Randomized Phase 2 Study of Panitumumab Versus Cetuximab in Colorectal Cancer (WJOG6510GTR)

K. Muro, D. Sakai, T. Satoh, 2020 .

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

Y. Ando, W. Ichikawa, Y. Sakata, 2015, British Journal of Cancer.

Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

I. Hyodo, K. Nishio, K. Muro, 2018 .

High Orotate Phosphoribosyltransferase Gene Expression Predicts Complete Response to Chemoradiotherapy in Patients with Squamous Cell Carcinoma of the Esophagus

Y. Hiasa, I. Hyodo, B. Matsuura, 2009, Oncology.

Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis

I. Hyodo, Yoshiyuki Yamamoto, T. Moriwaki, 2023, International Cancer Conference Journal.

Rationale and Study Protocol of the J-SAVER Study: A Phase II Study of S-1 on Alternate Days Combined with Bevacizumab in Patients Aged ≥75 Years with Metastatic Colorectal Cancer

I. Hyodo, M. Shimada, Kazuho Ikeda, 2017 .

The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.

E. Oki, A. Ohtsu, T. Kudo, 2017 .

Extragonadal retroperitoneal embryonal carcinoma successfully treated with chemotherapy.

I. Hyodo, S. Hirasaki, T. Moriwaki, 2003, Internal medicine.

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study

E. Baba, N. Sugimoto, I. Hyodo, 2018, Gastric Cancer.

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial

K. Nishio, K. Muro, Yoshiyuki Yamamoto, 2023, Targeted Oncology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases

Yoshiyuki Yamamoto, T. Moriwaki, T. Ikeda, 2021, International Cancer Conference Journal.

A phase II study of 5-FU/l-LV/oxaliplatin (mFOLFOX6) in patients with metastatic or unresectable small bowel adenocarcinoma.

E. Baba, H. Kitamura, I. Moriyama, 2014 .

Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy

E. Oki, M. Shiozawa, K. Ohtsubo, 2023, JCO precision oncology.

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

Y. Shimada, T. Oka, Ken Kato, 2008, British Journal of Cancer.

[A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin].

I. Hyodo, N. Nakano, Yoshiyuki Yamamoto, 2014, Gan to kagaku ryoho. Cancer & chemotherapy.

Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study.

I. Hyodo, Yoshiyuki Yamamoto, T. Matsumoto, 2014, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination

I. Hyodo, Yoshiyuki Yamamoto, T. Moriwaki, 2017, Internal medicine.

Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in metastatic colorectal cancer (mCRC).

I. Hyodo, T. Yoshino, N. Boku, 2014 .

Panitumumab-Induced Interstitial Lung Disease in a Case of Metastatic Colorectal Cancer

I. Hyodo, Yoshiyuki Yamamoto, T. Moriwaki, 2013, Oncology Research and Treatment.

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

I. Hyodo, M. Shimada, Kazuma Kobayashi, 2019, International Journal of Clinical Oncology.

Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial)

H. Sakurai, Yoshiyuki Yamamoto, Bryan J. Mathis, 2023, BMC Cancer.

Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

Yoshiyuki Yamamoto, T. Moriwaki, Takeshi Yamada, 2016, Journal of gastroenterology.

Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study.

E. Oki, N. Sugimoto, M. Gosho, 2017 .

High Orotate Phosphoribosyltransferase Gene Expression Predicts Complete Response to Chemoradiotherapy in Patients with Squamous Cell Carcinoma of the Esophagus

Y. Hiasa, I. Hyodo, B. Matsuura, 2009, Oncology.

Effect of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers: a population pharmacokinetic analysis

Yoshiyuki Yamamoto, K. Doki, T. Moriwaki, 2023, Cancer Chemotherapy and Pharmacology.

Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

Y. Kodera, Masato Nakamura, H. Ohdan, 2020, Gastric Cancer.